US vaccine advisory disruptions threaten childhood immunisation access and insurance coverage

Changes to the US Advisory Committee on Immunization Practices are causing uncertainty that could impact vaccine coverage, pharmacy workflows, and access for low-income families, raising concerns among health experts about the potential consequences for public health policy and immunisation programmes.

Disruption to the US vaccine advisory system is creating uncertainty that could reach far beyond Washington, affecting insurance coverage, pharmacy workflows and access for low-income families, according to Adam Colborn, vice-president of government affairs at the Academy of Managed Care Pharmacy. In an episode of “Worth a Shot” hosted by Drug Topics, Colborn said changes to the Advisory Committee on Immunization Practices are reshaping how vaccine recommendations are made and, in turn, how quickly patients can receive them.

Colborn said the revised committee charter broadens discussion beyond vaccines themselves and places more weight on possible safety concerns. He argued that this could distort the balance of the evidence, especially if rare adverse events are given more attention than the overall public health benefit of immunisation. AMCP has separately said it is troubled by recent changes to the childhood vaccine schedule, including the removal of the combined measles, mumps, rubella and varicella recommendation for children under four, as well as tighter COVID-19 access for people under 65.

The stakes are high because ACIP recommendations sit at the centre of vaccine coverage across much of the US health system. The Commonwealth Fund has explained that ACIP helps determine which vaccines are covered by employer plans, individual insurance, Medicare Part D, Medicaid and the Children’s Health Insurance Program. Its guidance also feeds directly into the Vaccines for Children programme, which provides free vaccines to about half of US children.

That link is what makes the current uncertainty especially worrying, Colborn said. He pointed to newly approved vaccines, updated formulations and expanded uses that may now be waiting for clear committee action. Under the Affordable Care Act’s preventive services rules, coverage is closely tied to ACIP recommendations, so any delay can slow reimbursement and create a patchwork of access. AMCP has also urged Health and Human Services Secretary Robert F. Kennedy Jr. to reinstate ACIP members after their removal, saying the move risks politicising a scientific body and undermining trust.

Pharmacists are likely to feel the impact first. Colborn noted that more than half of all immunisations are now given in pharmacies, and said most claims should still go through if a vaccine is administered in line with the rules in force on the date of service. Even so, he warned that confusion among pharmacists could mean more administrative work and less certainty for patients, especially parents trying to work out what their children are eligible to receive. For families depending on the Vaccines for Children programme, he said, the risk is particularly acute because the programme is legally linked to ACIP recommendations and accounts for almost half of childhood immunisations.